嵌合抗原受体T细胞疗法中的生物标志物。 - Suppr

Suppr

超能文献

Biomarkers in chimeric antigen receptor T-cell therapy.

作者信息

Kong Weimin, Lacey Simon F, Melenhorst Jan Joseph, Fraietta Joseph A

机构信息

Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USA.

出版信息

Biomark Med. 2018 May;12(5):415-418. doi: 10.2217/bmm-2018-0054. Epub 2018 Apr 26.

DOI:10.2217/bmm-2018-0054

PMID:29697279

Abstract

摘要

相似文献

Biomarkers in chimeric antigen receptor T-cell therapy.嵌合抗原受体T细胞疗法中的生物标志物。

Biomark Med. 2018 May;12(5):415-418. doi: 10.2217/bmm-2018-0054. Epub 2018 Apr 26.

Managing the toxicities of CAR T-cell therapy.管理嵌合抗原受体 T 细胞疗法的毒性。

Hematol Oncol. 2019 Jun;37 Suppl 1:48-52. doi: 10.1002/hon.2595.

[Not Available].[无可用内容]。

Bull Cancer. 2018 Dec;105 Suppl 2:S214-S217. doi: 10.1016/S0007-4551(19)30052-9.

Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.行业向细胞疗法的巨大飞跃：推动嵌合抗原受体 T 细胞（CAR-T）免疫疗法。

Curr Hematol Malig Rep. 2019 Feb;14(1):47-55. doi: 10.1007/s11899-019-0498-6.

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.嵌合抗原受体修饰 T 细胞治疗实体瘤的前景。

Mol Cancer. 2018 Jan 12;17(1):7. doi: 10.1186/s12943-018-0759-3.

CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.CRISPR/Cas9与嵌合抗原受体T细胞（CAR-T细胞），癌症免疫治疗中两项革命性技术的协作，癌症成功治疗指南。

Hum Immunol. 2018 Dec;79(12):876-882. doi: 10.1016/j.humimm.2018.09.007. Epub 2018 Sep 24.

Modelling CAR-T therapy in humanized mice.在人源化小鼠中模拟嵌合抗原受体T细胞（CAR-T）疗法。

EBioMedicine. 2019 Feb;40:25-26. doi: 10.1016/j.ebiom.2019.01.029. Epub 2019 Jan 18.

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤和实体瘤：临床数据现状、当前局限性和展望。

Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003.

Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.人源 GUCY2C 靶向嵌合抗原受体（CAR）表达 T 细胞消除结直肠癌转移。

Cancer Immunol Res. 2018 May;6(5):509-516. doi: 10.1158/2326-6066.CIR-16-0362. Epub 2018 Apr 3.

Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.优化针对 IL13Rα2 的嵌合抗原受体 T 细胞，以提高对神经胶质瘤的抗肿瘤疗效。

Mol Ther. 2018 Jan 3;26(1):31-44. doi: 10.1016/j.ymthe.2017.10.002. Epub 2017 Oct 5.

引用本文的文献

Potency testing of cell and gene therapy products.细胞和基因治疗产品的效价检测

Front Med (Lausanne). 2023 May 5;10:1190016. doi: 10.3389/fmed.2023.1190016. eCollection 2023.

Single-cell sorting based on secreted products for functionally defined cell therapies.基于分泌产物的单细胞分选用于功能定义的细胞治疗。

Microsyst Nanoeng. 2022 Jul 22;8:84. doi: 10.1038/s41378-022-00422-x. eCollection 2022.

Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib.使用idelalisib提高双阴性T细胞对急性髓系白血病的治疗效果。

Cancers (Basel). 2021 Oct 9;13(20):5039. doi: 10.3390/cancers13205039.

State-of-Art of Cellular Therapy for Acute Leukemia.急性白血病的细胞治疗进展。

Int J Mol Sci. 2021 Apr 27;22(9):4590. doi: 10.3390/ijms22094590.

Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.外周血嗜酸性粒细胞计数可预测抗 CD19 CAR-T 细胞疗法对 B 细胞非霍奇金淋巴瘤的疗效。

Theranostics. 2021 Mar 4;11(10):4699-4709. doi: 10.7150/thno.54546. eCollection 2021.

Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.针对表达在乳腺癌细胞上的叶酸受体 α 抗原的第四代嵌合抗原受体 T 细胞用于过继性 T 细胞疗法。

Breast Cancer Res Treat. 2021 Feb;186(1):25-36. doi: 10.1007/s10549-020-06032-3. Epub 2021 Jan 3.

Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells.基于体积单位的定量 PCR 方法用于嵌合抗原受体 T 细胞的复杂细胞动力学评估。

Sci Rep. 2020 Oct 21;10(1):17884. doi: 10.1038/s41598-020-74927-8.

The Roles of CCR7 for the Homing of Memory CD8+ T Cells into Their Survival Niches.CCR7在记忆性CD8 + T细胞归巢至其存活微环境中的作用。

Immune Netw. 2020 May 20;20(3):e20. doi: 10.4110/in.2020.20.e20. eCollection 2020 Jun.

Biomarkers in individualized management of chimeric antigen receptor T cell therapy.嵌合抗原受体T细胞疗法个体化管理中的生物标志物

Biomark Res. 2020 May 11;8:13. doi: 10.1186/s40364-020-00190-8. eCollection 2020.

Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.抗 CD19 CAR T 细胞治疗后寡克隆 T 细胞短暂扩增并表达 Tim-3 和 PD-1：一例报告。

Int J Mol Sci. 2018 Dec 19;19(12):4118. doi: 10.3390/ijms19124118.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验